Lexeo Therapeutics, Inc. Board of Directors

Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.

Mr. Rand Monaghan

Mr. Rand Monaghan

Vice President of Finance

Ms. Jenny R. Robertson J.D.

Ms. Jenny R. Robertson J.D.

Chief Business & Legal Officer

Dr. Eric Adler M.D.

Dr. Eric Adler M.D.

Chief Medical Officer & Head of Research

Dr. Sandi See Tai M.D.

Dr. Sandi See Tai M.D.

Chief Development Officer

Mr. Ryan McHenry

Mr. Ryan McHenry

VP & Corporate Controller

Dr. Ronald G. Crystal M.D.

Dr. Ronald G. Crystal M.D.

Co-Founder, Chief Scientific Advisor & Member of Scientific Advisory Board

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.